insulin glargine biosimilar
/ Lannett, HEC Pharm
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
September 15, 2022
A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers
(clinicaltrials.gov)
- P1 | N=104 | Completed | Sponsor: Lannett Company, Inc. | Recruiting ➔ Completed | Trial completion date: Feb 2023 ➔ Aug 2022
Trial completion • Trial completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus
March 31, 2022
A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers
(clinicaltrials.gov)
- P1 | N=104 | Recruiting | Sponsor: Lannett Company, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus
February 21, 2022
A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers
(clinicaltrials.gov)
- P1 | N=104 | Not yet recruiting | Sponsor: Lannett Company, Inc.
New P1 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus
December 20, 2021
"$LCI LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE https://t.co/breDTlg86W"
(@stock_titan)
IND
March 10, 2021
"$LCI Lannett Development Of Biosimilar Insulin Glargine Product Continues To Advance https://t.co/jDW66E5XEi"
(@stock_titan)
1 to 5
Of
5
Go to page
1